$HEM- Market Opening ValueHemostemix Inc. is a publicly traded biotechnology company listed on TSX-V marked with an opening of $0.285.
Pennystocks
$HEM volume increases Hemostemix Inc. is a biotechnology company listed on TSX-V with ticker symbol $HEM has shown growth in its volume. Today the volume is $8.62K.
Universal Ibogaine Inc. Market GraphUniversal Ibogaine Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0258-$0.1143 in the last 52 weeks.
$IBOGF’s 52 week range dataUniversal Ibogaine Inc. is a life science company listed on OTC with the ticker symbol $IBOGF. In the last 52 weeks the range of the lower and upper price is $0.0258-$0.1143.
Universal Ibogaine Delivering Excellence The Company newly reported that its common shares, coined as "JC4", have been accepted for trade on the Frankfurt Stock Exchange, or Boerse Frankfurt. In Canada, UI will keep trading on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the stock symbol IBOGF.
$IBO, Recognized as a powerful addiction interrupterOur mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
Potential aptitude of NCP-01 by Hemostemix Neuropathic pain synNeuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
$IBOGF stock evaluation and analysis$IBO stock ticker to Universal Ibogaine a company that provides ibogaine addiction treatment to patients tormented from opioid addiction in Canada is currently trading swiftly at $0.03734 with an evident hike.
$IBOGF accord with blue digital media calls for added benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
$IBOGF CEO Thoughts on H.C Wainwright.It gives UI great pleasure to announce that Nick Karos, CEO, will speak at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. On June 27, 2022, a hybrid online and offline event will take place. "H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
POSITIONAL TRADE, GHCL GHCL IS A MICROCAP STOCK, ,MCAP of 5500 cr
ROCE:-26% ROE:-24%
Fundamentally Strong stock
setup:- ENTRY(day timeframe) - only if we spot healthy green with good volume candle at our retest leval
entry should be taken above at the highh of that healthy candle
stoploss - only if the candle closes below our stoploss level
views are for educations purpose only
$IBO and its revolutionary addiction treatment protocolUI is developing an advanced holistic addiction treatment protocol, at its Kelburn Recovery Centre, that when combined with the planned ibogaine detox methodology is expected to transform the way we treat addiction and dramatically promote the welfare of families affected by addiction.
Blue digital media to highlight $IBO narrativeThe UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
$IBO an investor’s alluring stock investment$IBO has been elastic through the ebbs and flows of the market and have always maintained a tight toe hold in the Canadian venture exchange, its consistency to this day is what intrigues investors globally, the shares are trading at $0.05 with no such recorded loss
$IBOGF- 30 day Average Volume
The volume of $IBOGF is increasing day by day. In the last 30 days the average volume of $IBOGF has been recorded to be $4.42K.
$IBOGF’s Addiction treatmentUniversal Ibogaine Inc. is a life science company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical trial.
$IBOGF higher day rangeUniversal Ibogaine Inc. a life science company listed on OTC with the ticker symbol $IBOGF has been seen with a higher day range difference. The day range is $0.0367-$0.0385.
The Universal Ibogaine MissionUniversal Ibogaine is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the Ibogaine treatment protocol for opioid use disorder.
$IBO soon to commission ultra- modern addiction treatment centreAt the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
$IBOGF mounting rapidly on OTC with a huge 178% bump$IBOGF is trading swiftly in the market and observing a plenty of investor activities, the shares are trading live on OTC at $0.095 with an amazing 178% profit on value per share.
$IBO CO-Founder with flawless recordDr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
$IBO contract with blue digital media dictates further benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
Recent offering made by $HMTXF only for existing shareholdersThe offering constituting the private non-brokered placement of 15 Million units is only available to existing shareholders of the company, who as of the closing of business on May 16, 2022 hold common shares of Hemostemix
